Company History

 
September,
2020
Launched Ilumya® (tildrakizumab) for the treatment of plaque psoriasis, which is the first new biologics for Sun Pharma Japan in the Japanese market.
January,
2020
Merged with Pola Pharma Inc.
September,
2016
Announced the succession for manufacturing and marketing authorization for 14 long listed brands from Novartis Pharma K.K.
March,
2012
Sun Pharma Japan Limited was established in Japan